Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 15/20 | 0.60 |
| ▸ | MAOB | P27338 | 15/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | AGER | Q15109 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29276739 | 0.88 | LMNA (0.56) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL24590339 | 0.85 | NPC1 (0.45) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL30294204 | 0.84 | MAOA (0.60) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL14531586 | 0.84 | MAOA (0.60) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL1914666 | 0.82 | NPC1 (0.51) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL19851003 | 0.82 | CTRB1 (0.64) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL1915336 | 0.82 | AR (0.44) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL19851004 | 0.82 | AGER (0.70) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL29276772 | 0.80 | AGER (0.75) | MAOAMAOBNPC1RAB9AMAPT | |
| SCHEMBL10264427 | 0.79 | NPC1 (0.53) | MAOAMAOBNPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-9656953-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-05-23 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-08-07 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642278-B2 | Inhibition of cell proliferation | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-01 | — | — | US | disclosed |
| WO-2007062222-A2 | INHIBITION OF CELL PROLIFERATION | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254318-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | MAOA 3543/4885MAOB 3711/4885NPC1 4461/4885 |
| US-20140221658-A1 | INHIBITION OF CELL PROLIFERATION | RB1, RAF1, NRAS | MAOA 3543/4885MAOB 3711/4885NPC1 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.